In this study, we aimed to review the demographic, clinical, and laboratory characteristics of patients who were followed up and treated with the diagnosis of serum sickness-like reactions (SSLR) in our pediatric rheumatology clinic retrospectively and emphasize the importance of early diagnosis and treatment. The files of 29 patients who were hospitalized in the pediatric rheumatology clinic between September 2016 and March 2017 with the diagnosis of type 3 hypersensitivity reaction were reviewed retrospectively. Patient records including C-reactive protein, erythrocyte sedimentation rate, serum electrolytes, blood glucose, urea, and liver function were recorded by using the computerized patient database. The gender, age, length of hospital stay, accompanying clinical findings, family history of atopy, preceding infection, and drug usage data were obtained from the files of the patients. Twenty-nine patients with the diagnosis of type 3 hypersensitivity reaction were evaluated. Fifteen (51.7%) of the patients were male and 14 (48.3%) were female. The male to female ratio was 1.07. The age distribution of patients ranged from 18 to 192 months (mean ± SD 100.66 ± 53.75 months). The hospitalization duration was 3-16 days (mean ± SD 5.14 ± 3.20 days). The use of many drugs, especially antibiotics, has increased even in the treatment of viral upper air way infections. As a result, side effects have also increased. The most important of these is SSLR. However, this disease is not well recognized by clinicians.
Aim: Celiac disease is an immune-mediated systemic disorder elicited by the ingestion of gluten in genetically susceptible individuals. Gluten-free diet is the basis of treatment. In our study, it was aimed to evaluate the clinical findings of our patients with celiac disease before and after gluten-free diet therapy. Materials and Methods: The files of patients with celiac disease followed by Selcuk University Faculty of Medicine Pediatric Gastroenterology Outpatient Clinic between October 2012-October 2017 were reviewed retrospectively. Before and after gluten-free diet clinical characteristics (complaints, findings, body weight-height measurements and laboratory results) of patients were recorded. Before and after gluten-free diet clinical and laboratory findings of patients were compared. Results: The mean age of the 80 patients who were included in the study was 7.4 ± 4.3 years and 49 (61.3%) were girls. Six of the 80 patients (7.5%) had a family history of celiac disease. The rate of breastfeeding was 13.8% in less than 4 months of age in our patients. Timing of gluten introduction into the diet was 12.1% of the patients at 17 weeks earlier and 15.2% of the patients at 12 months later. The most common (55%) complaint among our patients was growth failure. However, 6 patients (7.5%) were overweight and 2 patients (2.5%) were obese. Chronic malnutrition was present in 25 (31.3%) of the patients before gluten-free diet treatment. There was no significant correlation between diagnosis age of celiac disease and grades of malnutrition (mild, moderate, severe). At the time of admission, 36 (45%) patients had loss of appetite, 35 (43.8%) patients had abdominal pain, 25 (31.3%) patients had dispeptic complaints, 21 (26.3%) patients had chronic diarrhea, 18 (22.5%) patients had abdominal swelling, 17 (21.3%) patients had constipation, and 12 (15%) patients had vomiting. In the laboratory findings, 32 (40%) patients had low ferritin and 26 (32.5%) patients had low hemoglobin levels. After gluten-free diet clinical and laboratory findings were improved at significant levels. Conclusion: The age of gluten introduction to the diet is important to the risk of developing celiac disease. Breast-feeding at the time of gluten introduction may reduce the risk of developing celiac disease. Growth retardation and chronic diarrhea are classic findings suggestive of celiac disease. However, it should be remembered that the patients with celiac disease may also be exposed to overweight, obese, constipation, or various other findings. When the gluten-free diet is followed, all symptoms associated with celiac disease are resolved. The treatment of the disease is a lifelong glutenfree diet.
We present the epidemiology, clinical features, and laboratory findings of 22 cases diagnosed with benign acute childhood myositis (BACM) after H1N1 infection in Konya, to observe and discuss this rare condition. This retrospective study was conducted in 22 children, diagnosed with BACM, who were brought to pediatric emergency department and pediatric rheumatology outpatient clinic of Selçuk University Medicine Faculty because of walking difficulties, between September 2017 and January 2018. Sixteen of the 22 (72.7%) patients enrolled in the study were male. The age of onset of symptoms ranged between 55 and 172 months. The interval between the onset of symptoms and the diagnosis was between 2 and 10 days. Throat pain was present in all cases as a prodromal symptom. Twelve (54.54%) of the cases presented with inability to stand or walk. Nine (40.90%) had gait abnormalities such as tip-toe walking, or a wide-based gait with a lordotic posture. Bilateral calf sensitivity was present in all cases. One patient had hypoactive deep tendon reflexes. In conclusion, although BACM is almost a typical clinical condition, we conclude that the recognition of the disease by family doctors and pediatricians is not sufficient and frequently underdiagnosed.
Bu çalışma çocukluk çağında en sık görülen vaskülit olan immünglobulin A vasküliti (IgAV;Henoch-Schönlein purpura) tanısıyla iç Anadolu yöresinde takip edilen çocuk hastaların klinik özelliklerini, laboratuvar değerlerini ve bunlar arasındaki istatistiksel ilişkiyi ortaya koymak amacıyla yapıldı.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.